JPH026336B2 - - Google Patents

Info

Publication number
JPH026336B2
JPH026336B2 JP56019056A JP1905681A JPH026336B2 JP H026336 B2 JPH026336 B2 JP H026336B2 JP 56019056 A JP56019056 A JP 56019056A JP 1905681 A JP1905681 A JP 1905681A JP H026336 B2 JPH026336 B2 JP H026336B2
Authority
JP
Japan
Prior art keywords
skin
particles
oxygen
fine
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56019056A
Other languages
Japanese (ja)
Other versions
JPS57134408A (en
Inventor
Chiaki Oohama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINATO SANGYO
Original Assignee
MINATO SANGYO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MINATO SANGYO filed Critical MINATO SANGYO
Priority to JP1905681A priority Critical patent/JPS57134408A/en
Publication of JPS57134408A publication Critical patent/JPS57134408A/en
Publication of JPH026336B2 publication Critical patent/JPH026336B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は皮膚活性化剤に関し、さらに詳しくは
人間及び動物の皮膚細胞を活性化でき、化粧品や
医薬品等に応用出来る皮膚活性化剤に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a skin activator, and more particularly to a skin activator that can activate human and animal skin cells and can be applied to cosmetics, pharmaceuticals, and the like.

周知の通り皮膚表面を健康にかつ清浄に保つた
めには皮膚の細胞の活性を高める必要がある。そ
して、細胞の活性を高めるためには血管中の血球
細胞等に吸着されているイオンの移動(電流の流
れ)を高めること、すなわち血行を促進すると共
に、酸素を必要なだけ十分に供給する必要がある
こともよく知られているところである。また、イ
オンの移動を高めるだけでは片手落であり、酸素
量を多くしただけでも不十分であるといわれてい
る。したがつてイオン移動を高めれば高める程、
酸素量を要し、そして酸素量が満たされるとイオ
ン移動が高進し、その相互相乗作用によつて活性
化が図られることが知られている。
As is well known, in order to keep the skin surface healthy and clean, it is necessary to increase the activity of skin cells. In order to increase cell activity, it is necessary to increase the movement (flow of current) of ions adsorbed to blood cells in blood vessels, in other words, to promote blood circulation and to supply sufficient oxygen as necessary. It is also well known that there is. Furthermore, it is said that merely increasing the movement of ions is insufficient, and that simply increasing the amount of oxygen is insufficient. Therefore, the higher the ion transport, the more
It is known that an amount of oxygen is required, and when the amount of oxygen is satisfied, ion movement increases, and activation is achieved through a mutual synergistic effect.

ところが従来から皮膚や筋肉の活性化のために
電気治療器や磁気治療器が多用されているが化粧
品や医薬品等には分子状酸素を誘導出来、かつ磁
性体をもつてなる化粧水、医薬品等は末だ皆無に
等しい。しかも上記の電気あるいは磁気治療器は
それなりの効果を呈しているものと思われるが、
これらは電気刺激又は磁気作用により皮膚及び筋
肉部位のイオン移動を高めるに等しく、それによ
り血行を促進し、もつてそれら部位の疲労回復を
図ろうとするものであり、酸素を供給しているも
のではないから、上述の周知の知見に照らしてみ
れば、皮膚等の細胞を真に活性化できず、不十分
であることは明白である。また、申すまでもな
く、従来の化粧品等によつて皮膚を単に清浄に保
つだけでは、上述した酸素の供給とイオン移動の
促進の両者を満足するには程遠く、効果的とはい
えなかつた。
However, although electric therapy devices and magnetic therapy devices have traditionally been widely used to activate the skin and muscles, cosmetics and medicines can induce molecular oxygen and contain magnetic substances such as lotions and medicines. The end is as good as nothing. Moreover, although the above-mentioned electric or magnetic therapy devices seem to have some degree of effectiveness,
These are equivalent to increasing the movement of ions in the skin and muscle areas through electrical stimulation or magnetic action, thereby promoting blood circulation and recovering from fatigue in those areas, and do not supply oxygen. Therefore, in light of the above-mentioned well-known knowledge, it is clear that cells such as the skin cannot be truly activated and are insufficient. Needless to say, simply keeping the skin clean with conventional cosmetics and the like is far from being effective in satisfying both the above-mentioned supply of oxygen and promotion of ion movement.

本発明は如上の点に鑑み開発されたもので、そ
の目的とするところは、人体や動物の皮膚表面を
効果的に清浄でき、化粧水等化粧品として使用で
きると共に、嫌気性菌の作用によつて生ずる皮膚
傷害を治療でき、また、手術後の傷口、眼病、口
腔内の炎症等の早期快復早期治療に利用でき、そ
して筋肉の疲れを治すことにも適用できる活性化
剤を提供するにある。
The present invention was developed in view of the above points, and its purpose is to effectively clean the skin surface of the human body and animals, to be able to be used as a cosmetic product such as lotion, and to use the action of anaerobic bacteria. To provide an activator that can be used to treat skin injuries that occur during surgery, can be used for early recovery from post-surgical wounds, eye diseases, oral inflammation, etc., and can also be applied to cure muscle fatigue. .

すなわち本発明は硫酸鉄を主成分とし、これに
ナトリウム、カルシウム、マグネシウム及び二酸
化マンガン、天然ゼオライト及び/又は酸性白土
からなる成分(微量成分)と高分子系分散安定剤
及び酸化防止剤とを添加してなり、かつ前記各成
分を微粒子状もしくは超微粒子状として水中にコ
ロイド分散させてなることを特徴とする皮膚活性
化剤を提供するものである。
That is, the present invention has iron sulfate as the main component, to which are added components (trace components) consisting of sodium, calcium, magnesium, manganese dioxide, natural zeolite and/or acid clay, a polymeric dispersion stabilizer, and an antioxidant. The present invention provides a skin activator characterized in that the above-mentioned components are colloidally dispersed in water in the form of fine particles or ultrafine particles.

本発明の皮膚活性化剤において、各成分は微粒
子状もしくは超微粒子状で、コロイド分散してい
ることが必要であり、微粒子状とは具体的には粒
径が300メツシユ以下のものをいうが好ましいの
は400〜500メツシユ程度のものである。
In the skin activator of the present invention, each component must be colloidally dispersed in the form of fine particles or ultrafine particles, and fine particles specifically refer to those with a particle size of 300 mesh or less. A preferred one is about 400 to 500 meshes.

本発明の皮膚活性化剤中の上記有効成分濃度は
用途などによつて適宜変わるが通常0.01〜2.0%
の範囲である。また有効成分中主成分の硫酸鉄は
65%が好ましい。また微量成分としての成分は35
%が好ましい。高分子系分散安定剤及び酸化防止
剤の添加量は微量かつ適当量であり、特に制限は
ない。
The concentration of the above-mentioned active ingredient in the skin activator of the present invention varies depending on the application, but is usually 0.01 to 2.0%.
is within the range of In addition, the main active ingredient, iron sulfate, is
65% is preferred. In addition, the trace ingredients are 35
% is preferred. The amounts of the polymeric dispersion stabilizer and antioxidant added are small and appropriate amounts, and are not particularly limited.

この皮膚活性化剤としての金属微粒子コロイド
溶液の1例をあげれば硫酸鉄65%、他の上記金属
塩、天然ゼオライト及び酸性白土を35%の配合比
で配合した微粒子又は超微粒子の粉末に、粉末5
重量部に対し水を20重量部の割合で加えて溶解さ
せ金属微粒子コロイド溶液とし、次いで天然酸化
防止剤と親水性に富んだ高分子系分散安定剤を混
入し、100〜200倍に希釈したものをあげることが
できる。また主成分硫酸鉄の代りに、二価の塩化
鉄を用いてもよい。上記高分子系分散安定剤添加
の理由は金属コロイド溶液中の金属コロイド微粒
子の凝集を防止し、分散を促進させてコロイド状
態を安定させるためである。酸化防止物質添加の
理由は、鉄化合物の自動酸化を防止し溶液使用時
に酸化作用をさせるためである。なお、鉄化合
物、他の成分の粉末粒子は微粒子であると超微粒
子であるとを問わないが超微粒子を採用すること
により、超微粒子が液の中により安定して分散し
ている金属超微粒子コロイド溶液とした場合に
は、本発明の効果は一層高まる。
An example of a colloidal solution of fine metal particles as a skin activator is fine or ultrafine powder containing 65% iron sulfate, other metal salts mentioned above, natural zeolite, and acid clay at a blending ratio of 35%. powder 5
Water was added at a ratio of 20 parts by weight to parts by weight to dissolve the metal particles to form a colloidal solution, and then a natural antioxidant and a highly hydrophilic polymeric dispersion stabilizer were mixed in and diluted 100 to 200 times. I can give things away. Further, divalent iron chloride may be used instead of the main component iron sulfate. The reason for adding the polymeric dispersion stabilizer is to prevent agglomeration of metal colloid fine particles in the metal colloid solution, promote dispersion, and stabilize the colloidal state. The reason for adding antioxidants is to prevent autooxidation of iron compounds and to cause oxidation to occur when the solution is used. Note that the powder particles of iron compounds and other ingredients may be either fine particles or ultrafine particles, but by using ultrafine particles, ultrafine metal particles can be dispersed more stably in the liquid. When used as a colloidal solution, the effects of the present invention are further enhanced.

本発明の皮膚活性化剤は皮膚への塗布を数日か
ら10日程度反復すると、皮膚表面のつやが出て、
細胞が活性化されたことが確認された。また筋肉
の疲労も早く回復した。さらに水虫等の嫌気性菌
による皮膚の傷害が早く治ることが確認された。
When the skin activator of the present invention is repeatedly applied to the skin for several to 10 days, the skin surface becomes glossy,
It was confirmed that the cells were activated. Muscle fatigue also recovered quickly. Furthermore, it was confirmed that skin injuries caused by anaerobic bacteria such as athlete's foot heal quickly.

このような効果を発揮する理由としては次のよ
うに考えられる。
The reason for this effect is thought to be as follows.

血管中の血球の表面にはイオンが付着してい
て、これが血液の循環として移動しているので
あるから、体内にはイオンの移動があり、すな
わち電流が流れているといわれる。したがつて
血管の周りには磁場があると考えられる。しか
も血液の流れは、心臓の脈動によつて生ずるの
であるから脈流であり、磁場が変化している。
そしてその磁場の変化は、その磁場を通る他の
血管中のイオン移動を促進し、血管に力が働い
ていると考えられる。
Ions are attached to the surface of blood cells in blood vessels, and these move as blood circulates, so it is said that there is a movement of ions in the body, that is, an electric current flows. Therefore, it is thought that there is a magnetic field around blood vessels. Moreover, the flow of blood is caused by the pulsation of the heart, so it is a pulsating flow, and the magnetic field changes.
It is thought that changes in the magnetic field promote the movement of ions in other blood vessels through the magnetic field, exerting a force on the blood vessels.

したがつて本発明の金属コロイド溶液を清浄
すべき又は患部の皮膚表面に塗布すると、皮膚
表面に金属コロイドの粒子(微粒子又は超微粒
子)が付着するがこの粒子は磁性体であるので
この粒子が付着した部位に磁気が誘導され易
い。すなわち、この粒子が付着した部位に磁場
が生じやすく、上述した磁場の変化によりイオ
ンの移動が活発になり、細胞が電気的に活性化
する。他方、鉄化合物の金属コロイドの微粒子
はその性質により空気中酸素を吸着し易いので
酸素を吸着し、それも分子状の酸素を吸着す
る。したがつて塗布された部位の皮膚組織内に
分子状酸素が溶け込み、当該部位を好気条件に
保ち、当該部位の細胞を活性化する。
Therefore, when the metal colloid solution of the present invention is applied to the skin surface of the area to be cleaned or affected, metal colloid particles (fine particles or ultrafine particles) adhere to the skin surface, but since these particles are magnetic, they Magnetism is likely to be induced in the attached area. That is, a magnetic field is likely to be generated at the site where these particles are attached, and the above-mentioned change in the magnetic field activates the movement of ions and electrically activates cells. On the other hand, fine particles of metal colloids of iron compounds tend to adsorb oxygen in the air due to their properties, so they adsorb oxygen and also adsorb molecular oxygen. Therefore, molecular oxygen dissolves into the skin tissue of the applied area, maintains the area in aerobic conditions, and activates cells in the area.

このようにイオン移動の促進と分子状酸素供
給の2点を満たすことによつて塗布接触した部
位の皮膚表面が活性化するものと思われる。ま
た筋肉等のコリをほぐすものと思われる。
It is thought that by satisfying the two requirements of promoting ion movement and supplying molecular oxygen, the skin surface of the area to which it is applied and comes into contact is activated. It is also thought to relieve stiffness in muscles, etc.

上述したように、皮膚細胞表面が好気条件に
保たれ分子状酸素が積極的に供給されるので嫌
気性菌は分子状酸素を分解する酵素を持たない
から当該部位の嫌気性菌が消滅する。従つて嫌
気性菌による傷害の治療に役立つ。
As mentioned above, the skin cell surface is maintained in aerobic conditions and molecular oxygen is actively supplied, so anaerobic bacteria do not have enzymes that decompose molecular oxygen, so the anaerobic bacteria in the area disappear. . It is therefore useful in treating injuries caused by anaerobic bacteria.

金属コロイドの粒子(微粒子、超微粒子)が
皮膚の表面に付着した状態において、磁場がか
かると、各粒子が磁化されて強く引きつけあ
う。その結果、各粒子の間にもぐり込んでいる
汚れの粒子が浮き上がり、それがふきとられて
皮膚表面が清浄になると思われる。
When metal colloid particles (fine particles, ultrafine particles) are attached to the surface of the skin and a magnetic field is applied, each particle becomes magnetized and strongly attracts each other. As a result, the dirt particles stuck between each particle are lifted up and wiped away, leaving the skin surface clean.

次に本発明を実施例に基づきさらに詳細に説明
する。
Next, the present invention will be explained in more detail based on examples.

実施例 次の配合で有効成分を水に分散させた。各成分
の粒径400〜325メツシユである。
EXAMPLE The active ingredient was dispersed in water with the following formulation. The particle size of each component is 400-325 mesh.

(成 分) (重量%) (a) 硫酸鉄 65 (b) カルシウム 12.5 (c) ナトリウム 7.5 (d) マグネシウム 10.0 (e) 二酸化マンガン 5.0 100.0 (f) 酸性白土 1.5 (g) 天然ゼオライト 1.5 103.0 まず、純水80を攪拌槽中に密閉状態で仕込
み、温度20℃に維持して、上記配合比の有効成分
のうち(a)〜(e)を投入して80分間回転数500r.p.mで
攪拌し、さらに(f)、(g)を投入して20分間攪拌す
る。(a)〜(g)の総量が25Kgとなるようにした。この
ようにして得たものを原液とする。原液は密閉状
態では安定である。
(Ingredients) (Weight%) (a) Iron sulfate 65 (b) Calcium 12.5 (c) Sodium 7.5 (d) Magnesium 10.0 (e) Manganese dioxide 5.0 100.0 (f) Acid clay 1.5 (g) Natural zeolite 1.5 103.0 First Pour 80% pure water into a stirring tank in a closed state, maintain the temperature at 20℃, add (a) to (e) of the active ingredients in the above mixing ratio, and stir at a rotation speed of 500 rpm for 80 minutes. Then, add (f) and (g) and stir for 20 minutes. The total amount of (a) to (g) was set to 25Kg. The product thus obtained is used as the stock solution. The stock solution is stable under closed conditions.

次にこれを50〜500倍に温水(35℃)で密閉状
態で希釈し、酸化防止剤としてビタミンE(α−
トロフエロール)及び高分子系分散安定剤として
ステアリン酸を0.007%投入して製品とした(PH
6)。
Next, this was diluted 50 to 500 times with warm water (35℃) in a sealed state, and vitamin E (α-
tropherol) and 0.007% stearic acid as a polymeric dispersion stabilizer (PH
6).

試験例 1 水虫の被検体15名に実施例で得た微粒子コロイ
ド液を1日1回、1回の噴霧量2c.c.で塗布したと
ころ10日内外で全員が完治した。
Test Example 1 The microparticle colloid liquid obtained in the example was applied once a day to 15 test subjects suffering from athlete's foot at a spray amount of 2 c.c., and all of them recovered completely within 10 days.

試験例 2 切傷を4針縫つて接合した接合部に実施例で得
た金属微粒子コロイド液を1日1回2c.c.ずつ毎日
噴霧したところ、1ケ月でほぼ傷口が癒着して、
接合傷あとが消え原形に復した。これは普通なら
ば治癒に1年間を要するところである。
Test Example 2 When the metal fine particle colloid liquid obtained in the example was sprayed once a day at 2c.c. on the joint where the cut was stitched with 4 stitches, the wound almost healed in one month.
The bonding scar disappeared and it returned to its original shape. Normally, this would take a year to heal.

試験例 3 結膜炎の患者に、実施例で得た金属微粒子コロ
イド液をさらに200倍に希釈した液を昼間と夜間
各1回噴霧量各2c.c.ずつ吹きつけて治療したとこ
ろ2日間で完治した。
Test Example 3 A patient with conjunctivitis was treated by spraying a 200-fold dilution of the fine metal particle colloid solution obtained in Example at a spray volume of 2 c.c. once each day and night, resulting in complete recovery within 2 days. did.

Claims (1)

【特許請求の範囲】[Claims] 1 硫酸鉄を主成分とし、これにナトリウム、カ
ルシウム、マグネシウム及び二酸化マンガン、天
然ゼオライト及び/又は酸性白土からなる成分と
高分子系分散安定剤及び酸化防止剤とを添加して
なり、かつ前記各成分を微粒子状もしくは超微粒
子状として水中にコロイド分散させてなることを
特徴とする皮膚活性化剤。
1 The main component is iron sulfate, to which are added components consisting of sodium, calcium, magnesium, manganese dioxide, natural zeolite and/or acid clay, a polymeric dispersion stabilizer and an antioxidant, and each of the above A skin activator characterized by comprising components colloidally dispersed in water in the form of fine or ultrafine particles.
JP1905681A 1981-02-13 1981-02-13 Skin activating agent Granted JPS57134408A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1905681A JPS57134408A (en) 1981-02-13 1981-02-13 Skin activating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1905681A JPS57134408A (en) 1981-02-13 1981-02-13 Skin activating agent

Publications (2)

Publication Number Publication Date
JPS57134408A JPS57134408A (en) 1982-08-19
JPH026336B2 true JPH026336B2 (en) 1990-02-08

Family

ID=11988767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1905681A Granted JPS57134408A (en) 1981-02-13 1981-02-13 Skin activating agent

Country Status (1)

Country Link
JP (1) JPS57134408A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62180029U (en) * 1986-05-06 1987-11-16
JP3608059B2 (en) * 1995-12-05 2005-01-05 株式会社アドバンス Cosmetics
JP2002080376A (en) * 2000-06-06 2002-03-19 Ibe:Kk Biologically active agent and medicine
DE102005020467A1 (en) * 2005-04-15 2006-10-19 Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH Agent for the therapy and prophylaxis of skin diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4920320A (en) * 1972-06-24 1974-02-22
JPS5426336A (en) * 1977-07-31 1979-02-27 Kanebo Ltd Makeup base composition
JPS5498341A (en) * 1978-01-18 1979-08-03 Shiyouichi Moriya Production of composite substance as bactericidal medium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4920320A (en) * 1972-06-24 1974-02-22
JPS5426336A (en) * 1977-07-31 1979-02-27 Kanebo Ltd Makeup base composition
JPS5498341A (en) * 1978-01-18 1979-08-03 Shiyouichi Moriya Production of composite substance as bactericidal medium

Also Published As

Publication number Publication date
JPS57134408A (en) 1982-08-19

Similar Documents

Publication Publication Date Title
ES2552731T3 (en) Electricity generation particles and their use
US5554361A (en) Processed product for skin and hair treatment
JP2002520348A5 (en)
JP2001010960A (en) Topcal zinc composition
CN109528755A (en) One kind composition containing nano-sulfur and its application
US4755384A (en) Externally applied antispasmatic products
CA1243957A (en) Compositions for cosmetic, health- and body- preserving use
JPH0647535B2 (en) Anti-inflammatory composition
JPH026336B2 (en)
Eby Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and review of actions of gallium III
US11759479B2 (en) Compositions comprising a manganese mineral and methods of use
JPH11139927A (en) Pigment composition for body makeup and its production
US20060165611A1 (en) Composition for Treating and Preventing Periodontal Disease and Method of Use
US6686392B1 (en) Lipidic zinc compounds and use for treatment of prostatic hypertrophy
CN102670420A (en) Negative ion mask
WO2012004782A2 (en) Oral remedial mineral replenishment (omr) preparation
JP3534470B2 (en) Method for producing bath or massage agent
JP2001039855A (en) Agent for thalassotherapy consisting essentially of coral sand and marine deep water and thalassotherapy
RU2686075C1 (en) Biologically active agent for treating locomotor diseases and a method of treating locomotor diseases
CN1287762C (en) Bathing milk salt
JP4799724B2 (en) Biofunction-activating substances incorporated in bathing agents, packs, and toothpaste additives
JP3241173B2 (en) Bath additive
JP2000273024A (en) Hair tonic
JP2003040783A (en) Tungstic acid salt or molybdic acid salt and addition product of reishi spore useful as pharmaceutical product and health food
RU2221551C1 (en) Balneal curative-prophylactic agent "bishol"